Article

Genomic Profiling to Contextualize the Results of Intervention for High-Risk Smoldering Myeloma

2023-08-31

Abstract excerpt

<h4>ABSTRACT</h4> Early intervention for High-Risk Smoldering Multiple Myeloma (HR-SMM) achieves deeper and more prolonged responses compared to Newly Diagnosed (ND) MM. It is unclear if beneficial outcomes of interventional studies in HR-SMM are due to treatment of less complex, susceptible disease or inaccuracy in clinical definition of cases entered. Here, to gain greater biologic insight into treatment outcome...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 01923b9a-ffef-5a28-b1d7-b89f0ac3a3ec
DOI: 10.1101/2023.08.30.23294483

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genomic Profiling to Contextualize the Results of Intervention for High-Risk Smoldering MyelomaDOI 10.1101/2023.08.30.23294483Read

Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.Semantic proximity Read

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.Semantic proximity Read

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease ProgressionSemantic proximity Read

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitionsSemantic proximity Read

Genomic patterns of progression in smoldering multiple myeloma.Semantic proximity Read

Genomic landscape of multiple myeloma and its precursor conditionsSemantic proximity Read

The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Semantic proximity Read

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneSemantic proximity Read

Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profilingSemantic proximity Read

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read

Evolution of multiple myeloma from a genomic perspective.Semantic proximity Read

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisSemantic proximity Read